ALPHAMAB ONCOLO.DL-000002 (3NK) — Tangible Net Worth Ratio
ALPHAMAB ONCOLO.DL-000002 (3NK) has a Tangible Net Worth Ratio of 98.8% as of December 2025. This metric is calculated by deducting intangible assets (€19.70 Million) from net assets (€1.71 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore 3NK year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
ALPHAMAB ONCOLO.DL-000002 Tangible Net Worth Ratio (2021–2025)
This chart shows how ALPHAMAB ONCOLO.DL-000002's Tangible Net Worth Ratio has changed across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 98.8%, reflecting net assets of €1.71 Billion with intangible assets of €19.70 Million EUR. For live market cap and overall valuation, see 3NK market cap.
Annual Tangible Net Worth Ratio for ALPHAMAB ONCOLO.DL-000002 (2021–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025, covering 5 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore ALPHAMAB ONCOLO.DL-000002 capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 98.8% | €1.71 Billion | €19.70 Million | €2.10 Billion | ▼ 0.0 pp |
| 2024 | 98.9% | €1.83 Billion | €20.20 Million | €2.24 Billion | ▲ +0.1 pp |
| 2023 | 98.8% | €1.67 Billion | €20.69 Million | €2.14 Billion | ▲ +0.1 pp |
| 2022 | 98.6% | €1.56 Billion | €21.18 Million | €2.12 Billion | ▼ -0.2 pp |
| 2021 | 98.8% | €1.87 Billion | €21.68 Million | €2.71 Billion | — |